论文部分内容阅读
Objective: The tyrosine kinase inhibitor nmtedanib is m clinical development for the treatment of idiopathic pulmonary fibrosis.In the present study, we explore icotinib, a novel tyrosine kinase inhibitor mode of action, icotinib was tested in human lung fibroblasts and mouse models of lung fibrosis by aerosol.